Please sign in to follow a disease.
A radioactive clue that could spare thousands from thyroid surgery
NCT ID NCT05591092
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This trial tests whether a special imaging scan using a small amount of radioactive iodine (iodine-123) can tell the difference between benign and cancerous thyroid nodules before surgery. Currently, biopsy alone can't always make that call, so many people undergo surgery just to find out. If the scan proves accurate, it could help doctors avoid unnecessary operations. The study involves adults with suspicious thyroid nodules who will receive the tracer and undergo planar and SPECT/CT imaging before their scheduled surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Iodine-123, a radioactive tracer used in imaging scans
- What this could lead to
- If successful, this imaging approach could help doctors identify cancerous thyroid nodules without surgery, sparing many patients from unnecessary operations.
- What could go wrong
- This is a very small early study, and the imaging may not reliably distinguish benign from malignant nodules. There is also a small radiation exposure risk from the tracer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
2 people
The number who actually took part.
- Started
-
Nov 2023
- Finished
-
Jan 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Mayo Clinic patients with biopsy-proven indeterminate follicular thyroid lesions scheduled for surgery.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age \> 18 years * Any gender * Patients will have had no therapy for their thyroid nodule prior to enrollment * Negative urine pregnancy test within 48 hours before the administration of radiopharmaceutical in women of childbearing potential * Follicular neoplasm or suspicious of follicular neoplasm, cytopathology on biopsy of thyroid nodule * Any outside fine needle aspiration (FNA) reports are to be reviewed by a Mayo pathologist * Nodules 1-4 cm with solid appearance on ultrasound * Ultrasound images and report documented in medical record, including the size of the nodule and location (upper, mid or lower portion of the thyroid lobe) * At least 2/3 of either thyroid lobe without nodules should be present to allow for the measurement of uptake in unaffected thyroid tissue * Thyroid stimulating hormone (TSH) 0.3-3.0 mIU/L * Patient is scheduled or being considered for surgical resection of the nodule * I-123 planar and Single Photon Emission Computed Tomography (SPECT)/Computed Tomography (CT) can be scheduled at least 2 days after biopsy and before surgery Exclusion Criteria: * Recent iodinated contrast, including intravenous (IV) and oral CT contrast or interventional vascular or cardiac study (within 6 weeks) * Hurthle cell adenoma * Current thyroid hormone supplementation * Current use of anti-thyroid medications (methimazole or propylthiouracyl) * Less than 2 days after thyroid nodule FNA/biopsy * Presence of another nodule of similar size in the same area of thyroid lobe, which could impair localization of the nodule on SPECT/CT images * Less than 2/3 of normal thyroid tissue present in either thyroid lobe without nodules * Positive pregnancy test * All women who are breastfeeding
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Thyroid gland follicular carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.